Management of agitation and aggression associated with Alzheimerʼs disease: controversies and possible solutions
Authors:
- Clive BallardCBClive Ballard
- Anne CorbettACAnne Corbett
- Ramilgan ChitramohanRCRamilgan Chitramohan
- Das AarslandDADas Aarsland
- 1 November 2009
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Psychiatry
- Vol. 22 (6) , 532-540
Abstract
Behavioral and psychological symptoms of dementia (BPSD) are frequent among people with Alzheimer's disease and other dementias, commonly confer risk to the person and others, and present a significant management challenge for clinicians. The purpose of this review is to describe the current state of knowledge regarding management of BPSD, with a particular focus on agitation. There is increasing evidence to support the value of simple psychological interventions and staff-training programs as a first-line management strategy for agitation prior to pharmacotherapy. The most widely prescribed pharmacological treatments - atypical antipsychotics - have a modest but significant beneficial effect in the short-term treatment of aggression (over 6-12 weeks), but limited benefits in longer term therapy. In addition, there have been increasing concerns regarding the potential for serious adverse outcomes, including stroke and death. The potential pharmacological alternatives to atypical antipsychotics with the most encouraging preliminary evidence include memantine, carbamazepine and citalopram. Large prospective, randomized, placebo-controlled trials are needed to establish the role of agents other than neuroleptics as clinical therapies for the treatment of BPSD and studies are urgently needed to evaluate BPSD treatments in non-Alzheimer dementias.Keywords
This publication has 72 references indexed in Scilit:
- Effect of a Serotonin Reuptake Inhibitor on Irritability, Apathy, and Psychotic Symptoms in Patients With Alzheimer's DiseaseThe Journal of Clinical Psychiatry, 2009
- Metabolic Changes Associated With Second-Generation Antipsychotic Use in Alzheimer’s Disease Patients: The CATIE-AD StudyAmerican Journal of Psychiatry, 2009
- A controlled trial of antidepressants in patients with Parkinson disease and depressionNeurology, 2009
- Clinical Symptom Responses to Atypical Antipsychotic Medications in Alzheimer’s Disease: Phase 1 Outcomes From the CATIE-AD Effectiveness TrialAmerican Journal of Psychiatry, 2008
- A Randomised, Blinded, Placebo-Controlled Trial in Dementia Patients Continuing or Stopping Neuroleptics (The DART-AD Trial)PLOS Medicine, 2008
- Point and 5‐year period prevalence of neuropsychiatric symptoms in dementia: the Cache County StudyInternational Journal of Geriatric Psychiatry, 2007
- Neuropsychiatric symptoms (behavioral and psychological symptoms of dementia) and the development of dementia treatmentsInternational Psychogeriatrics, 2007
- A Placebo-Controlled Trial of Valproate for Agitation and Aggression in Alzheimer’s DiseaseDementia and Geriatric Cognitive Disorders, 2006
- Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's DiseaseNew England Journal of Medicine, 2006
- Systematic Review of Psychological Approaches to the Management of Neuropsychiatric Symptoms of DementiaAmerican Journal of Psychiatry, 2005